en · de · es · fr · pt
faq-desk.peptides7250.com › Faq › Handling Storage And Analytical Methods — Evidence Review

Handling Storage And Analytical Methods — Evidence Review

By Editorial Desk · published 2026-06-21 · last reviewed 2026-07-15 · Faq

Lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling Storage And Analytical Methods

Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.

Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.

Molecular Background and Naming

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

Cjc-1295 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderVisual descriptor; not a measure of purity
Solubility classFreely soluble in waterAqueous dissolution may require gentle mixing
Typical storage (powder)−20 °C or below, desiccatedProtect from light and ambient moisture
Typical storage (solution)2–8 °C, short termFreeze aliquots where longer holding is needed
Purity assessmentReversed-phase HPLC, area percentValues depend on column, gradient, and detection wavelength

Background and Molecular Features

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

Related pages on this site

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

Background and Naming Conventions

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Mechanism and Pharmacokinetics

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Supporting material

A neurotransmitter prodrug, or neurotransmitter precursor, is a drug that acts as a prodrug of a neurotransmitter. A variety of neurotransmitter prodrugs have been developed and used in medicine. They can be useful when the neurotransmitter itself is not suitable for use as a pharmaceutical drug owing to unfavorable pharmacokinetic or physicochemical properties, for instance high susceptibility to metabolism, short elimination half-life, or lack of blood–brain barrier permeability. Besides their use in medicine, neurotransmitter prodrugs have also been used as recreational drugs in some cases.

It is a bioactive sphingoid which derives from the sphinganine. It is formed by a sphingoid and an amino alcohol and it constitutes the conjugated base of 1-deoxymethylsphinganine (1+). Its role is accepting a hydron from a donor via its organic amino compound; it is a Brønsted base. It is also known as deoxymethyl-SA, (2R)-1-aminoheptadecan-2-ol and 1-desoxymethylsphinganine. The molecular weight of this compound is 271,48 g/mol and its molecular formula is C17H37NO, which means it has 17 carbons. In relation to its appearance, it has a powder form. Other physical and chemical properties are not certainly known.

Fluorine-18 (18F, also called radiofluorine) is a fluorine radioisotope which is an important source of positrons. Its half-life is 109.734 minutes, less than two hours, and one of the shortest of radioisotopes with use outside research. It decays by positron emission 96.7% of the time and electron capture 3.3% of the time. Both modes of decay yield stable oxygen-18.

Sources: en.wikipedia.org

Notes from published material

In this case the equation can be used if the flow speed of the gas is sufficiently below the speed of sound, such that the variation in density of the gas (due to this effect) along each streamline can be ignored. Adiabatic flow at less than Mach 0.3 is generally considered to be slow enough. It is possible to use the fundamental principles of physics to develop similar equations applicable to compressible fluids. There are numerous equations, each tailored for a particular application, but all are analogous to Bernoulli's equation and all rely on nothing more than the fundamental principles of physics such as Newton's laws of motion or the first law of thermodynamics.

== Uses == The plant is used in the traditional medicine of Indonesia, Malaysia and Vietnam where the root of the plant is boiled in water, and the water is consumed as a tonic. The flower and fruits are used to treat dysentery, and the root is used for malaria, fever, and other ailments.

Besides being cheap and convenient, the wet chemical approach allows fine control of the particle's chemical composition. Even small quantities of dopants, such as organic dyes and rare earth metals, can be introduced in the reagent solutions end up uniformly dispersed in the final product.

Immediately after the 1948 war, the Israel-Palestinian conflict shifted to a low intensity conflict between the IDF and Palestinian fedayeen. In the 1956 Suez Crisis, the IDF's first serious test of strength after 1949, the new army captured the Sinai Peninsula from Egypt, which was later returned. In the 1967 Six-Day War, Israel conquered the Sinai Peninsula, Gaza Strip, West Bank (including East Jerusalem) and Golan Heights from the surrounding Arab states, changing the balance of power in the region as well as the role of the IDF. In the following years leading up to the Yom Kippur War, the IDF fought in the War of Attrition against Egypt in the Sinai and a border war against the Palestine Liberation Organization (PLO) in Jordan, culminating in the Battle of Karameh. The surprise of the Yom Kippur War and its aftermath completely changed the IDF's procedures and approach to warfare. Organizational changes were made and more time was dedicated to training for conventional warfare. In the following years the army's role slowly shifted again to low-intensity conflict, urban warfare and counter-terrorism. An example of the latter was the successful 1976 Operation Entebbe commando raid to free hijacked airline passengers being held captive in Uganda. During this era, the IDF also mounted a successful bombing mission in Iraq to destroy its nuclear reactor. It was involved in the Lebanese Civil War, initiating Operation Litani and later the 1982 Lebanon War, where the IDF ousted Palestinian guerilla organizations from Lebanon.

Sources: en.wikipedia.org

Frequently asked questions

How should the dry powder be stored?

Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.

Does a solution need to be used immediately?

There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.

Which analytical methods confirm identity?

Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.

Is CJC-1295 a natural hormone?

No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.

Network